Ratings Nipro Corporation

Equities

8086

JP3673600007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-15 EDT			5-day change	1st Jan Change
1,196 ^JPY	-2.84%		-5.42%	+8.08%

04-12	Jefferies Adjusts Nipro’s Price Target to 1,400 Yen From 1,200 Yen, Keeps at Hold	MT
01-11	Jefferies Adjusts Nipro's Price Target to 1,200 Yen From 1,000 Yen, Keeps at Hold	MT

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company appears to be poorly valued given its net asset value.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company does not generate enough profits, which is an alarming weak point.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
NIPRO CORPORATION	+8.08%	1.28B	C+
ABBOTT LABORATORIES	-4.89%	181B	C+
MEDTRONIC PLC	+2.18%	112B	C
BECTON, DICKINSON AND COMPANY	-2.64%	67.92B	A
DEXCOM, INC.	+4.45%	50.1B	B-
CENCORA, INC.	+8.41%	44.27B	B-
HOYA CORPORATION	+9.39%	40.41B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.82%	31.95B	B
WEST PHARMACEUTICAL SERVICES, INC.	-0.14%	25.82B	A-
TERUMO CORPORATION	+17.27%	25.29B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes